title: Comparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthma.
abstract: OBJECTIVE
  To compare the safety of regadenoson, a selective agonist of A2A adenosine receptors, combined with low-level exercise, between subjects with mild/moderate chronic obstructive pulmonary disease (COPD) and asthma referred for myocardial perfusion imaging (MPI).
  
  
  METHODS
  We studied 116 patients, of whom 67 had COPD and 49 asthma (62 % men, mean age 68.3 ± 11.3 years, range 31 - 87 years). Patient demographics, past medical history, medications, clinical symptoms during stress and changes in blood pressure (BP) and heart rate (HR) were evaluated.
  
  
  RESULTS
  Both groups were comparable with regard to hypertension, dyslipidaemia, diabetes and medications with the exception of a higher rate of use of anticholinergics in patients with COPD and of antileukotrienes in asthmatics (58.2 % vs. 28.6 % and 1.5 % vs. 14.3 %, respectively; all p < 0.01). There was a higher incidence of dyspnoea in COPD patients and of headache and feeling hot in asthmatic patients (40.3 % vs. 22.4 %, 6 % vs. 18.4 % and 10.4 % vs. 26.5 %, respectively; all p < 0.05). Although there was no difference in the incidence of other adverse events, we observed a higher frequency in asthmatics of flushing, dry mouth, sweating and fatigue (1.5 % vs. 6.1 %, 14.9 % vs. 24.5 %, 0 % vs. 4.1 % and 37.3 % vs. 49 %, respectively). Adverse events were self-limiting, except in three patients who suffered persistent dyspnoea (2 of 67 COPD patients; 1 of 49 asthma patients) requiring theophylline administration. We observed no significant changes in BP among either group, but there was a tendency towards a higher increase in systolic BP in COPD patients following regadenoson administration (148.3 ± 27.6 vs. 154.6 ± 31.0 mmHg, p = 0.056).
  
  
  CONCLUSIONS
  This study showed a good safety profile in our series of COPD and asthma patients undergoing MPI. Regadenoson was well tolerated by all patients, with dyspnoea, headache and feeling hot showing differences between groups.
authors.forename: Carlos
authors.initials: C
authors.lastname: Salgado Garcia
authors.affiliation: Department of Nuclear Medicine, Hospital Juan Ramon Jimenez, Ronda Norte, s/n, 21005, Huelva, Spain, carlos.salgado.garcia@gmail.com.
authors.forename: Carlos Salgado
authors.initials: CS
authors.lastname: Garcia
authors.forename: Amelia
authors.initials: A
authors.lastname: Jimenez Heffernan
authors.forename: Amelia Jimenez
authors.initials: AJ
authors.lastname: Heffernan
authors.forename: Elena
authors.initials: E
authors.lastname: Sanchez de Mora
authors.forename: Carlos
authors.initials: C
authors.lastname: Ramos Font
authors.forename: Juana
authors.initials: J
authors.lastname: Lopez Martin
authors.forename: Francisco
authors.initials: F
authors.lastname: Rivera de los Santos
authors.forename: Ignacio
authors.initials: I
authors.lastname: Ynfante Milá
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D005080:Exercise Test; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D011687:Purines / Q000009:adverse effects* / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D012449:Safety; D013312:Stress, Physiological / Q000187:drug effects
chemical_list: D011687:Purines; D011720:Pyrazoles; C430916:regadenoson